Scienture Holdings (SCNX) Income from Discontinued Operations (2016 - 2024)
Scienture Holdings' (SCNX) quarterly Income from Discontinued Operations came in at -$209161.0 in Q2 2024, down 182.3% year-over-year from $254157.0 in Q3 2023, and down 100.75% quarter-over-quarter from $27.9 million in Q1 2024.
Powered by 
Analysis
Scienture Holdings (SCNX) Income from Discontinued Operations (2016 - 2024) Analysis & Trends
Scienture Holdings has disclosed Income from Discontinued Operations across 4 years of filings, most recently posting -$209161.0 for Q2 2024.
- In Q2 2024, Income from Discontinued Operations fell 182.3% year-over-year to -$209161.0; the TTM figure through Jun 2024 stood at $19.1 million (up 3619.4% YoY), while the FY2024 annual figure was $27.3 million, up 391.75% from the prior year.
- Income from Discontinued Operations came in at -$209161.0 for Q2 2024 at Scienture Holdings, down from $27.9 million in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of $27.9 million in Q1 2024 to a low of -$5.2 million in Q4 2023.
- Average Income from Discontinued Operations over 3 years is $2.4 million, with a median of -$99939.5 recorded in 2022.
- Year-over-year, Income from Discontinued Operations sank 1681.24% in 2023 and jumped 5978.14% in 2024.
- Over 3 years, Income from Discontinued Operations stood at -$188268.0 in 2022, then sank by 2682.04% to -$5.2 million in 2023, then jumped by 96.01% to -$209161.0 in 2024.
- Per Business Quant data, the three most recent Income from Discontinued Operations figures were -$209161.0 in Q2 2024, $27.9 million in Q1 2024, and -$5.2 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | - |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | - |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | - |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | Scienture Holdings | 15.19 Mn | 15.19 Mn | 335,779.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -209,161.00 |
| Mar 31, 2024 | 27.88 Mn |
| Dec 31, 2023 | -5.24 Mn |
| Sep 30, 2023 | -3.35 Mn |
| Jun 30, 2023 | 254,157.00 |
| Mar 31, 2023 | 458,684.00 |
| Sep 30, 2022 | -188,268.00 |
| Mar 31, 2022 | -11,611.00 |
| Dec 31, 2016 | -381,575.00 |
| Sep 30, 2016 | -547,403.00 |
| Jun 30, 2016 | -456,864.00 |
| Mar 31, 2016 | -201,175.00 |